Duggan C M, Mitchell G, Nikles C J, Glasziou P P, Del Mar C B, Clavarino A
Centre for General Practice, University of Queensland.
Aust Fam Physician. 2000 Dec;29(12):1205-9.
To pilot single patient trials designed to improve decision making about stimulant use for attention deficit hyperactivity disorder (ADHD) in general practice.
Patients previously stabilised on dexamphetamine were enrolled from a general practice. Each undertook a six week same patient randomised, double blind, placebo controlled crossover comparison of dexamphetamine with placebo for ADHD. Rating scales were completed weekly by self, parent and teacher.
Three of the four patients were clear responders to dexamphetamine (including a noncompleter, as his results still demonstrated a clear response). The results were clinically useful in each case. Management was confirmed for three patients and changed for one (who ceased dexamphetamine).
Prescribing stimulant medications only to children with diagnosed ADHD and who are found to respond, limits use of these worrisome drugs to those who will respond, and minimises their use in those who will not benefit.
开展单病例试验,以改善全科医疗中针对注意力缺陷多动障碍(ADHD)使用兴奋剂治疗的决策制定。
从一家全科诊所招募此前使用右旋苯丙胺病情已稳定的患者。每位患者均进行为期六周的同病例随机、双盲、安慰剂对照交叉试验,比较右旋苯丙胺与安慰剂治疗ADHD的效果。患者本人、家长和教师每周完成评定量表。
4例患者中有3例对右旋苯丙胺反应明显(包括1例未完成试验者,因其结果仍显示明显反应)。结果在每种情况下均具有临床实用性。3例患者治疗方案得到确认,1例患者治疗方案改变(停用右旋苯丙胺)。
仅对已确诊且有反应的ADHD儿童开具兴奋剂药物,可将这些令人担忧的药物的使用限制在有反应的儿童中,并尽量减少在无获益儿童中的使用。